Results 11 to 20 of about 3,203 (180)

Comparison of the Effects of Paricalcitol and Calcitriol on Vascular Calcification in Patients Undergoing Chronic Hemodialysis [PDF]

İstanbul Medical Journal, 2021
Introduction:Secondary hyperparathyroidism is considered an unconventional risk factor of vascular calcification in hemodialysis patients (HPs). An important factor of vascular calcification is vitamin D receptor activator used in the treatment of ...
Süleyman Karaköse, Zeynep Bal, Siren Sezer   +2 more
doaj   +2 more sources

Paricalcitol for Secondary Hyperparathyroidism in Renal Transplantation [PDF]

Journal of the American Society of Nephrology, 2015
Secondary hyperparathyroidism contributes to post-transplant CKD mineral and bone disorder. Paricalcitol, a selective vitamin D receptor activator, decreased serum parathyroid hormone levels and proteinuria in patients with secondary hyperparathyroidism.
M. Trillini, M. Cortinovis, P. Ruggenenti, J. R. Loaeza, K. Courville, C. Ferrer Siles, S. Prandini, F. Gaspari, A. Cannata, A. Villa, A. Perna, E. Gotti, M. R. Caruso, D. Martinetti, G. Remuzzi, N. Perico   +15 more
openaire   +3 more sources

The vitamin D analogue paricalcitol attenuates hepatic ischemia/reperfusion injury through down-regulation of Toll-like receptor 4 signaling in rats

Archives of Medical Science, 2016
Introduction : Recent studies have revealed that vitamin D and its synthetic analogues have a protective effect on experimental ischemia/reperfusion (I/R) models in several organs, but little is known about its effect on the liver.
Min Sung Kim, Soyoung Lee, Namhee Jung, Kiho Lee, Jinwoo Choi, Sang-Hoon Kim, Jinhyun Jun, Won-Mee Lee, Yeonsoo Chang, Donghee Kim   +9 more
doaj   +2 more sources

The pleiotropic effects of paricalcitol: Beyond bone-mineral metabolism [PDF]

Nefrología (English Edition), 2016
Secondary hyperparathyroidism (SHPT) is a common complication in patients with chronic kidney disease (CKD) that is characterised by elevated parathyroid hormone (PTH) levels and a series of bone-mineral metabolism anomalies.
Jesús Egido, Alberto Martínez-Castelao, Jordi Bover, Manuel Praga, José Vicente Torregrosa, Elvira Fernández-Giráldez, Carlos Solozábal   +6 more
doaj   +2 more sources

Paricalcitol reduces oxidative stress and inflammation in hemodialysis patients [PDF]

BMC Nephrology, 2012
Background Treatment with selective vitamin D receptor activators such as paricalcitol have been shown to exert an anti-inflammatory effect in patients on hemodialysis, in addition to their action on mineral metabolism and independently of parathyroid ...
Izquierdo María, Cavia Mónica, Muñiz Pilar, de Francisco Angel LM, Arias Manuel, Santos Javier, Abaigar Pedro   +6 more
doaj   +2 more sources

Effect of paricalcitol on mineral bone metabolism in kidney transplant recipients with secondary hyperparathyroidism

Nefrología (English Edition), 2015
Introduction: Secondary hyperparathyroidism is highly prevalent in kidney transplant recipients, and commonly results in hypercalcaemia; an association to osteopenia and bone fractures has also been observed.
Francisco José Borrego Utiel, Juan Antonio Bravo Soto, María José Merino Pérez, Isabel González Carmelo, Verónica López Jiménez, Teresa García Álvarez, Yelenei Acosta Martínez, María Auxiliadora Mazuecos Blanca   +7 more
doaj   +2 more sources

Efecto de paricalcitol sobre el metabolismo mineralóseo en pacientes trasplantados renales con hiperparatiroidismo secundario

Nefrología, 2015
Introducción: El hiperparatiroidismo secundario es muy prevalente en pacientes trasplantados renales. Cursa con frecuencia con hipercalcemia y se ha asociado al desarrollo de osteopenia y fracturas óseas.
Francisco José Borrego Utiel, Juan Antonio Bravo Soto, María José Merino Pérez, Isabel González Carmelo, Verónica López Jiménez, Teresa García Álvarez, Yelenei Acosta Martínez, María Auxiliadora Mazuecos Blanca   +7 more
doaj   +2 more sources

Exploring the potential effect of paricalcitol on markers of inflammation in de novo renal transplant recipients. [PDF]

PLoS ONE, 2020
Following a successful renal transplantation circulating markers of inflammation may remain elevated, and systemic inflammation is associated with worse clinical outcome in renal transplant recipients (RTRs).
Hege Kampen Pihlstrøm, Thor Ueland, Annika E Michelsen, Pål Aukrust, Franscesca Gatti, Clara Hammarström, Monika Kasprzycka, Junbai Wang, Guttorm Haraldsen, Geir Mjøen, Dag Olav Dahle, Karsten Midtvedt, Ivar Anders Eide, Anders Hartmann, Hallvard Holdaas   +14 more
doaj   +2 more sources

Efficacy and safety of paricalcitol in patients undergoing hemodialysis: a meta-analysis

Drug Design, Development and Therapy, 2019
Yang Liu,1 Ling-Yun Liu,2 Ye Jia,1 Mei-Yan Wu,1 Yan-Yan Sun,3 Fu-Zhe Ma1 1Department of Nephrology, The First Hospital of Jilin University, Changchun, China; 2Department of Andrology, The First Hospital of Jilin University, Changchun, China; 3Department
Liu Y, Liu LY, Jia Y, Wu MY, Sun YY, Ma FZ   +5 more
doaj   +1 more source

Asymmetric Dimethylarginine (ADMA) Levels Are Lower in Hemodialysis Patients Treated With Paricalcitol

Kidney International Reports, 2017
Chronic kidney disease is a major public health problem. In the last decade, it has been shown that the early stages of chronic kidney disease are associated with an inflammatory condition involving an increased risk of cardiovascular morbidity and long ...
Elena Oliva-Damaso, Nestor Oliva-Damaso, Francisco Rodriguez-Esparragon, Juan Payan, Alberto Marañes, Yanet Parodis, Lopez Eduardo Baamonde-Laborda, Nicanor Vega Diaz, Jose Carlos Rodriguez-Perez   +8 more
doaj   +2 more sources